- Products
Products
Founded in 2004, DIURNAL®, a NEUROCRINE BIOSCIENCES® Company, is a European, UK-headquartered specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency.
- Clinical Resources
Clinical Resources
Diurnal is dedicated to developing new treatments to aid lifelong treatment for rare and chronic endocrine conditions
- R&D
R&D
Our expertise and innovative research activities focus on circadian-based endocrinology (mimicking the body's natural hormone levels) to develop products for rare and chronic endocrine conditions.
- Transparency
- Careers
Careers
Diurnal is a rapidly growing global specialty pharmaceutical company with a highly integrated and very committed team. We're always looking for talented individuals who share our vision. Visit this section to view our current opportunities.
- Awards
Awards
A limited number of awards is available each year, and all applications will be judged objectively by an independent panel.
Alkindi® (hydrocortisone granules in capsules for opening) is Diurnal’s first commercialised medicine and is indicated as replacement therapy of adrenal insufficiency in infants, children and adolescents (from birth to less than 18 years old)1. Alkindi was approved through the centralised paediatric use marketing authorisation (PUMA) route in the European Union in 2018.
Alkindi is an immediate-release hydrocortisone preparation that has been specifically designed to meet the dosing needs of paediatric patients with adrenal insufficiency for whom no licensed, child-friendly products exist in Europe. Currently, pharmacists often compound (grind) hydrocortisone tablets to a fine powder and reconstitute it in individual capsules or sachets to achieve the lower doses required for children. This compounding is highly variable and often results in inaccurate dosing2. Alkindi is manufactured using commercially proven technology in four doses: 0.5mg, 1mg, 2mg and 5mg, in order to give maximum flexibility to clinicians in tailoring the treatment to the child. Taste-masking excipients that are acceptable for paediatric use eliminate the bitter taste of hydrocortisone, potentially increasing compliance. Alkindi has a shelf life exceeding two years which is significantly longer than that of existing unlicensed hydrocortisone products.
1. Alkindi Summary of Product Characteristics
2. Neumann et al 2017 Quality of compounded hydrocortisone capsules used in the treatment of children. European Journal of Endocrinology 177, 239–242
